A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

Cancer Chemotherapy and Pharmacology
Andrew H KoMargaret A Tempero

Abstract

No standard of care exists for patients with metastatic pancreatic cancer following progression on first-line chemotherapy. Based on potential for additive or synergistic activity by concurrent inhibition of VEGF and EGFR, we conducted a phase II study evaluating the combination of bevacizumab plus erlotinib in this patient population. Patients with metastatic pancreatic adenocarcinoma, ECOG performance status 0-1, and previous exposure to 1-3 systemic therapies (at least one gemcitabine-based) were eligible. Treatment consisted of bevacizumab 15 mg/kg every 21 days plus erlotinib 150 mg daily. Thirty-six patients were enrolled, including eight who had previously received VEGF-targeted therapy and nine prior erlotinib. Median number of treatment cycles was 2 (range, 1-7). Common toxicities included rash (72%), diarrhea (25%), venous thromboembolic events (15%), and hypertension (11%). One patient demonstrated partial response and seven others stable disease for >2 cycles. CA19-9 decline ≥25% was observed in 4/26 patients with baseline levels >2x ULN. Estimated median time to progression was 40 days (95% CI, 35-41 days) and median survival 102 days (95% CI, 74-117 days), with a 6-month survival rate of 22%. Baseline concentratio...Continue Reading

References

May 15, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y D JungL M Ellis
Mar 29, 2005·The Oncologist·Howard A BurrisArthur Staddon
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C LouvetUNKNOWN GISCAD
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hedy L KindlerEverett E Vokes
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Volker HeinemannRalf Wilkowski
Jan 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BoeckV Heinemann
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard HerrmannUNKNOWN Central European Cooperative Oncology Group
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald M BukowskiDavid McDermott
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeCharles S Fuchs
Dec 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maura N DicklerClifford A Hudis
Jan 27, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G K PhilipsUNKNOWN Cancer and Leukemia Group B
Mar 25, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemMalcolm J Moore
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher G WillettRakesh K Jain
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jul 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hedy Lee KindlerRichard M Goldberg

❮ Previous
Next ❯

Citations

Mar 20, 2010·Langenbeck's Archives of Surgery·André L MihaljevicJörg Kleeff
Jan 1, 2014·Drug Design, Development and Therapy·Jun-ya UedaSuresh Awale
Mar 8, 2014·World Journal of Gastroenterology : WJG·Evan J Walker, Andrew H Ko
Sep 2, 2015·Expert Review of Anticancer Therapy·Concetta Elisa OnestiPaolo Marchetti
Mar 6, 2013·Expert Opinion on Pharmacotherapy·Pavan Mankal, Eileen O'Reilly
Mar 27, 2015·Expert Opinion on Investigational Drugs·Edward J KimRichard J Bold
Feb 7, 2012·Drug Discovery Today·Jaco KraanJan W Gratama
Oct 21, 2015·Critical Reviews in Oncology/hematology·Adnan M NagrialDesmond Yip
Dec 3, 2014·Seminars in Oncology·Darshil T JhaveriElizabeth M Jaffee
Mar 4, 2017·Expert Opinion on Emerging Drugs·Kalliopi AndrikouStefano Cascinu
Jan 1, 2010·Cancers·Cristina Rabascio, Francesco Bertolini
Jul 10, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Enrique GrandeAlfredo Carrato
Jan 30, 2013·Nature Reviews. Clinical Oncology·Sook Ryun ParkShivaani Kummar
May 1, 2019·Cancers·Madelaine G van MackelenberghHanneke W M van Laarhoven
Nov 18, 2014·World Journal of Gastroenterology : WJG·Jeffrey M Sutton, Daniel E Abbott
Sep 14, 2016·World Journal of Gastroenterology : WJG·Alexandra R LewisMairead G McNamara
Jun 3, 2015·World Journal of Gastroenterology : WJG·Andrada SeiceanRadu Seicean
Jul 28, 2016·Current Opinion in Gastroenterology·Ashok K SalujaSulagna Banerjee
Dec 29, 2018·Expert Opinion on Pharmacotherapy·Maria DiabPhilip A Philip
Jan 7, 2017·Journal of Investigative Surgery : the Official Journal of the Academy of Surgical Research·Efstathios T Pavlidis, Theodoros E Pavlidis
Jul 13, 2018·Investigational New Drugs·Christian DittrichPhilipp Buchner
Jan 19, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David S YooDavid M Brizel
Aug 8, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew H KoW Michael Korn
Feb 14, 2021·The AAPS Journal·Zhiyi ZhangMin Liu
Jan 6, 2021·Cancer Metastasis Reviews·Bayan Al-ShareMaria Diab
Mar 18, 2021·Advanced Biology·Xiaoxiao LiuYuexiang Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

© 2021 Meta ULC. All rights reserved